Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis

Summary

This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.

Timeline

Start

2024-08-19

Primary completion

2025-03-13

Completion

2025-03-31

Outcome

Met primary endpoint

release “Achieved Primary and Key Secondary Endpoints in Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3” aclaristx.com ↗

Drugs

Indications